Disease · EFO_0009579

postpartum hemorrhage

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. postpartum hemorrhage. Diseases, record EFO_0009579. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009579

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: postpartum hemorrhage; Open Targets
Open Targets ID: EFO_0009579; Open Targets
Other names: postpartum haemorrhage; Open Targets
NCI Thesaurus: C92853; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 24 drugs, from DailyMed and TTD; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBETOCIN	CHEMBL3301668	Protein	Approval	TTD	21	19	19	Drugs and targets
ERGONOVINE	CHEMBL119443	Small molecule	Approval	TTD	3	2	2	Drugs and targets
CARBOPROST TROMETHAMINE	CHEMBL1237105	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
VASICINE	CHEMBL2163791	Small molecule	Approval	TTD	1	0	0	Drugs and targets
OXYTOCIN	CHEMBL395429	Protein	Phase 3	ClinicalTrials.gov	30	30	30	Drugs and targets
MISOPROSTOL	CHEMBL606	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	19	19	19	Drugs and targets
ERGONOVINE MALEATE	CHEMBL1213135	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
VON WILLEBRAND FACTOR HUMAN	CHEMBL4298126		Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
IRON ISOMALTOSIDE 1000	CHEMBL4298046		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets22

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGFR	Prostaglandin F2-alpha receptor	4	Prostanoid FP receptor agonist	Approval	https://conductscience.org/library/genes/5737	Drugs and targets
F7	Coagulation factor VII	2	Coagulation factor VII exogenous protein	Unknown	https://conductscience.org/library/genes/2155	Drugs and targets
OXTR	Oxytocin receptor	2	Oxytocin receptor agonist	Approval	https://conductscience.org/library/genes/5021	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 1	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 1	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 1	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets
DRD1	D(1A) dopamine receptor	1	Dopamine D1 receptor antagonist	Early phase 1	https://conductscience.org/library/genes/1812	Drugs and targets
F10	Coagulation factor X	1	Coagulation factor X exogenous protein	Unknown	https://conductscience.org/library/genes/2159	Drugs and targets

1 to 10 of 22

See all 22 targets

Trials73

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01085006	The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery	Phase 1/2	100	2011-01-25	Hemorrhage	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT04344860	Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial	Phase 3	20	2025-10-31	Von Willebrand Diseases, Postpartum Hemorrhage	TRANEXAMIC ACID, VON WILLEBRAND FACTOR HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00872469	World Maternal Antifibrinolytic Trial	Phase 3	20,060		Postpartum Haemorrhage	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03254628	Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program Evaluation	Not applicable	3,440		Postpartum Hemorrhage, Neonatal Asphyxia	MISOPROSTOL, OXYTOCIN	Its record names the disease	ClinicalTrials.gov
NCT04723979	NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL		3,322		Post Partum Hemorrhage	EPTACOG ALFA (ACTIVATED)	Its record names the disease	ClinicalTrials.gov
NCT00116350	Misoprostol for the Treatment of Postpartum Hemorrhage	Not applicable	1,786		Postpartum Hemorrhage	MISOPROSTOL, OXYTOCIN	Its record names the disease	ClinicalTrials.gov
NCT06235749	Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery	Not applicable	1,180		Elective Cesarean Delivery	CALCIUM GLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT02424201	Comparative Study on the Effects of Sublingual Misoprostol in Addition to Standard AMTSL in Low Risk Parturients in LASUTH, Ikeja.	Early phase 1	660		Primary Postpartum Haemorrhage	MISOPROSTOL	Its record names the disease	ClinicalTrials.gov
NCT07278037	Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage		648		Postpartum Hemorrhage, Delivery Complication, Cesarean Section Complications, Perinatal Problems	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02163616	Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study	Phase 3	635		Postpartum Hemorrhage	MISOPROSTOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 73

See all 73 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tranexamic Acid vs Normal Saline Infusion: serious adverse events	0 of 50	0 of 50	100	NCT01085006	Trial comparisons
rVWF plus TA vs rVWF alone: deaths from any cause	0 of 10	0 of 10	20	NCT04344860	Trial comparisons
rVWF plus TA vs rVWF alone: serious adverse events	0 of 10	0 of 10	20	NCT04344860	Trial comparisons

Papers from its trials48

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32120445	RESULT	1	PubMed
31962259	RESULT	1	PubMed
31010345	RESULT	1	PubMed
30322584	RESULT	1	PubMed
30122082	RESULT	1	PubMed
28040124	RESULT	1	PubMed
27536161	RESULT	1	PubMed
26591047	RESULT	1	PubMed
19757270	RESULT	1	PubMed
40902088	DERIVED	1	PubMed

1 to 10 of 48

See all 48 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009579

GET https://conductscience.org/api/diseases/v1/EFO_0009579/drugs?page=2

API reference For AI assistants